Business
Hyundai ADM Bio Voluntarily Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy
Hyundai ADM Bio (KOSDAQ symbol 187660) today announced the voluntary withdrawal of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating Penetrium™ in combination with docetaxel, as part of a strategic redirection to focus on immunotherapy-based combinations. The company plans to resubmit an IND application within this month for a new trial combining its ECM-targeting agent, Penetrium™, with immune checkpoint inhibitors.
About this update from Penetrium Bioscience Inc.
[{"type":"text","content":"Declares a strategic pivot to lead the post-patent immunotherapy combination era","length":80,"tagName":"p","attribs":{}},{"type":"text","content":"SEOUL, South Korea, May 13, 2025 /PRNewswire/ -- Hyundai ADM Bio (KOSDAQ symbol 187660) today announced the voluntary withdrawal of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating Penetrium™ in combination with docetaxel, as part of a strategic redirection to focus on immunotherapy-based combinations. The company plans to resubmit an IND application within this month for a new trial combining its ECM-targeting agent, Penetrium™, with immune checkpoint inhibitors.","length":509,"tagName":"p"},{"type":"image","alt":"Hyundai ADM Bio (PRNewsfoto/Hyundai ADM Bio)","displaySize":"","headline":null,"caption":"Hyundai ADM Bio (PRNewsfoto/Hyundai ADM Bio)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":389,"url":"https://media.zenfs.com/en/prnewswire.com/0e77d78232f762344081a079d3420588"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qb_adIkAVwMljxmCFHBVgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY4NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0e77d78232f762344081a079d3420588","width":400,"height":389}},"href":"https://mma.prnewswire.com/media/2603446/Hyundai_ADM_Bio_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This decision reflects not merely the termination of a single trial, but a forward-looking repositioning aligned with the structural transformation of the global oncology landscape and a refined scientific understanding of tumor microenvironment dynamics.","length":255,"tagName":"p"},{"type":"text","content":"Merck's immune checkpoint inhibitor Keytruda® has been investigated in over 1,600 combination trials worldwide. With key patents scheduled to expire starting in 2028, major biopharmaceutical companies such as Celltrion and Samsung Bioepis are accelerating efforts to secure biosimilar pipelines and manufacturing infrastructure.","length":332,"tagName":"p"},{"type":"text","content":"At the American Association for Cancer Research (AACR) Annual Meeting 2025, key themes that emerged across presentations and investor discussions included the expanded access to immunotherapy, diversification of combination approaches, and competitive advancement of next-generation o...